Public Release: 

Nanoparticles show early promise in reducing inflammation after brain bleed

ISC 16 basic science tips

American Heart Association

Nanoparticles from ceria - a rare earth metal - might lessen inflammation in the brain following a bleeding stroke (hemorrhagic stroke), according to research presented at the American Stroke Association's International Stroke Conference 2016.

Researchers from South Korea noted that previous studies have shown that ceria nanoparticles have strong antioxidant properties as well as anti-inflammatory effects. This study investigated whether the tiny particles could reduce inflammation that occurs just after an intracerebral hemorrhage (bleeding within the brain).

In a lab experiment, researchers studied a type of white blood cell called macrophages taken from the brains of rats and applied ceria nanoparticles to them. Compared with untreated macrophages, the macrophages treated with the nanoparticles secreted fewer inflammation-promoting chemicals.

In a second experiment, researchers injected ceria nanoparticles in 10 rats with brain bleeds. Compared with 10 untreated rats, the treated rats had less damage at the stroke site and less water accumulation, suggesting less inflammation in the area of the stroke, researchers said.

###

Additional Resources:

Any available multimedia related to these tips are on the right column of this link http://newsroom.heart.org/news/basic-science-tip-sheet-3127213?preview=288bf38a9020a77868a1001b3426486c

Future vaccine may help lower blood pressure long-term
Gut bacteria may impact body weight, fat and good cholesterol levels
Understanding stroke risk factors
Join the AHA/ASA's Support Network to talk with others going through similar journeys including depression after stroke.
Follow news from the American Stroke Association's International Stroke Conference 2016 via Twitter: @HeartNews #ISC16.

Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.